U.S. markets closed

Eliem Therapeutics, Inc. (ELYM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
16.14-0.14 (-0.86%)
At close: 4:00PM EDT
16.14 0.00 (0.00%)
After hours: 07:29PM EDT

Eliem Therapeutics, Inc.

23515 NE Novelty Hill Road
Suite B221 #125
Redmond, WA 98053
United States
425 276 2300

Full Time Employees25

Key Executives

NameTitlePayExercisedYear Born
Mr. Robert W. Azelby M.B.A.Pres, CEO & Director678kN/A1968
Ms. Erin M. LavelleExec. VP, COO & CFO502.88kN/A1978
Ms. Valerie Morisset Ph.D.Chief Scientific Officer and Exec. VP of R&D497.15kN/A1970
Mr. James B. Bucher J.D.Exec. VP & Gen. CounselN/AN/A1966
Ms. Amy Chappell M.D.Chief Medical OfficerN/AN/AN/A
Ms. Jo Palmer-Phillips Ph.D.Chief Devel. OfficerN/AN/AN/A
Julio E. VegaSec.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain and ETX-155 for major depressive disorder, perimenopausal depression, and focal onset seizures. The company also develops preclinical pipeline programs, such as Kv7 Program for pain epilepsy; and Anxiolytic for the treatment of generalized anxiety. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.

Corporate Governance

Eliem Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.